이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

양극성 우울증에 대한 MYDAYIS®의 8주 다중 사이트 연구

2026년 10월 22일 업데이트: Mark Frye, Mayo Clinic

An 8 Week Randomized Double Blind Placebo Controlled Multi-site Study Assessing Efficacy and Safety of MYDAYIS® (D-amphetamine / L-amphetamine) for Bipolar Depression

This protocol is a Phase 2 multi-site study which aims to evaluate the safety and effectiveness of MYDAYIS® as adjunctive therapy for adults with bipolar depression. Results from this study WILL NOT be used to contribute to an approval of MYDAYIS ® for this indication.

연구 개요

연구 유형

중재적

등록 (실제)

77

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Minnesota
      • Rochester, Minnesota, 미국, 55905
        • Mayo Clinic in Rochester
    • Ohio
      • Mason, Ohio, 미국, 45040
        • Lindner Center of Hope

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria

  1. Male or female between 18 and 65 years of age
  2. Bipolar I or II disorder as confirmed by structured diagnostic clinical interview for DSM-IV-TR.
  3. Subsyndromal depressive symptoms or major depressive episode unresponsive to steady and stable (ie, at least 2 weeks) mood stabilization (eg, lithium, valproate, lamotrigine, carbamazepine/oxcarbamazepine, and/or atypical antipsychotic therapy) and non-psychotropic medication.
  4. Antidepressant therapy is allowed in the study as long as patients are also on a mood stabilizer. Patients will be enrolled provided that any needed modifications to the antidepressant would be made at least two weeks prior to randomization.
  5. Patients receiving psychotherapy will be allowed to be randomized provided therapy frequency does not change during the 8-week blinded phase.
  6. Symptom severity score on the Quick Inventory for Depressive Symptomatology - Clinician (QIDS-C16) ≥9, and the Clinical Global Impression for Bipolar Illness (CGI-BP) Depression Severity Scale ≥ 3.
  7. Patients on stimulants for comorbid attention deficit disorder (ADHD) and/or binge eating disorder (BED) will be enrolled provided that the stimulant can be tapered and discontinued at least one week prior to randomization; symptom severity inclusion criteria 4.1.3 or presence of subsyndromal symptoms must be met again prior to randomization.
  8. Patients with a prescribed opiate (eg. hydroxicodone) or other pain intervention for acute or chronic pain management will be allowed provided they: 1) use of a prescribed opiate or other pain intervention at a recommendation dose and established duration; 2) show no evidence of prescription misuse; 3) do not meet abuse or dependence criteria by SCID; 4) no known significant pharmacological interactions.
  9. Ability to travel for the assessment visits.

Exclusion Criteria

  1. Inability to provide written informed consent.

  2. Inability to understand English.

  3. Score less than 86% correct (ie, one wrong) on comprehension assessment that reviews study goals.

  4. Clinically significant signs of acute suicidality from any of the following assessments:

    1. Response of > 2 on question #12 of QIDS-C or
    2. Response = 3 on the SCID Module A- #A19
  5. Medically serious suicide attempt within the past 6 months (medically serious defined as an ED evaluation and procedure and/or admit to inpatient unit such as internal medicine, cardiac, or ICU).

  6. Concomitant treatment with monoamine oxidase inhibitors (MAOIs); also, within 14 days following discontinuation of treatment with a monoamine oxidase inhibitor.

  7. Baseline Young Mania Rating Scale (YMRS) score ≥ 12.

  8. Patients with active psychosis (measured by a score >4 on YMRS question #8) or a diagnosis of schizophrenia, schizoaffective disorder, delusional, or schizophreniform disorder identified by structured clinical interview for DSM-IV-TR.

  9. Active abuse or dependence of alcohol, opiates, or cannabis (nicotine dependence will be an exception) by structured clinical interview for DSM-IV-TR; patients meeting full remission for at least 3 months can be randomized.

  10. Positive toxicology screen for drugs of abuse (ie, cocaine, methamphetamine, illegal opiates).

  11. Positive toxicology screen for cannabis and a cannabis use disorder by structured clinical interview for DSM-IV-TR. Participants who use cannabis for recreational or medicinal purposes and fail the toxicology screen can potentially be included in the study only if they take the CUDIT-R and score a 12 or less

  12. Known lifetime history of cocaine or methamphetamine abuse or dependence identified by structured clinical interview for DSM-IV-TR.

  13. Active stimulant prescription abuse or dependence by structured clinical interview for DSM-IV-TR; patients meeting full remission for at least 6 months can be randomized.

  14. Known lifetime history of stimulant-induced mania.

  15. Known hypersensitivity, such as angioedema or anaphylaxis, to amphetamines or other ingredients of MYDAYIS.

  16. Clinically unstable medical disease.

  17. Known history of a structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormality, coronary artery disease, stroke, or other serious cardiovascular problems.

  18. ECG with clinically significant arrhythmias, conduction abnormalities, or voltage criteria met for left ventricular hypertrophy (unless cleared by cardiology consultation).

  19. Uncontrolled hypertension (>160/100) or tachycardia (heart rate >110).

  20. History of grand mal seizure; history of febrile seizure as infant permitted.

  21. Established vasculopathy or history of Raynaud's phenomena.

  22. Narrow angle glaucoma.

  23. Chronic kidney disease (CKD) > stage IIIa (GFR 40-59).

  24. Tourette syndrome.

  25. Women who are pregnant, lactating or of child-bearing potential not using at least one adequate contraceptive measure (ie, hormonal contraception-birth control pills, intrauterine devices (IUD), tubal ligation or condoms during sexual intercourse).

  26. Current positive test for SARS-CoV-2; those with previous COVID-19 illness and those who test positive for SARS-CoV-2 any time after starting study drug or placebo will be included.

  27. Otherwise excluded for administrative reasons and/or clinician judgment.

  28. Daily use of lorazepam (Ativan) at doses > 2 mg per day (or dose equivalent: clonazepam (Klonopin) > 1 mg, alprazolam (Xanax) > 1-2 mg, or diazepam (Valium) >20 mg) [58].

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 삼루타

무기와 개입

참가자 그룹 / 팔
개입 / 치료
활성 비교기: Mydayis - Active

MYDAYIS®, Oral administration, dose regimen for Double blind phase and open label phase.

12.5 mg x 7 days. 25 mg x 7 days 37.5 mg x 14 days 50 mg daily x 28 days

Randomized, parallel - group, double-blind, placebo-controlled, flexible-dose adjunctive trial of MYDAYIS®

다른 이름들:
  • d-암페타민 / l-암페타민
위약 비교기: Placebo

Matching placebo, Oral administration, dose regimen for Double blind phase and open label phase.

12.5 mg x 7 days. 25 mg x 7 days 37.5 mg x 14 days 50 mg daily x 28 days

Matching placebo

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Change in Montgomery-Asberg Depression Rating Scale (MADRS) Score
기간: Baseline to week 8

The Montgomery-Åsberg Depression Rating Scale (MADRS) is a clinician-administered tool used to measure the severity of depression and track changes during treatment. Total scores range from 0 to 60, with higher numbers indicating more severe depressive symptoms. The outcome measure was the mean percent reduction from baseline in participants' total MADRS score, with greater percent reductions indicating greater improvement in depressive symptoms.

Baseline to week 8
Change in Montgomery-Asberg Depression Rating Scale (MADRS) Score-Open Label Extension
기간: Week 8 to Week 16

The Montgomery-Åsberg Depression Rating Scale (MADRS) is a clinician-administered tool used to measure the severity of depression and track changes during treatment. Total scores range from 0 to 60, with higher numbers indicating more severe depressive symptoms. The outcome measure was the mean absolute change from week 8 to week 16 in participants' total MADRS score. Negative values indicate a reduction in depressive symptom severity.

Week 8 to Week 16

2차 결과 측정

결과 측정
측정값 설명
기간
Change in Quick Inventory for Depressive Symptomatology (QIDS-C-16 and QIDS-SR-16) Score
기간: Baseline to Week 8

The QIDS-C-16 (Quick Inventory of Depressive Symptomatology - Clinician) and QIDS-SR-16 (Quick Inventory of Depressive Symptomatology - Self Report) are 16-item questionnaires designed to assess the severity of depressive symptoms. They are widely used by healthcare providers to monitor treatment progress and symptom changes over time. They are scored the same. Scores are calculated by summing the responses to nine core symptom domains. The total score ranges from 0 to 27, with higher scores indicating greater depression severity. The outcome measure was mean percent reduction from baseline in total QIDS-C-16 and QIDS-SR-16 scores, with greater reductions indicating greater improvement in depressive symptoms.

Baseline to Week 8
Remission
기간: Baseline to Week 8

The number of subjects who had treatment remission defined as having a Montgomery-Asberg Depression Rating Scale (MADRS) score < 10. (Score Range 0-60)

Baseline to Week 8
Change in General Anxiety Disorder 7-item (GAD-7) Scale Score
기간: Baseline to Week 8 visit 10

The GAD-7 scale is used to assess anxiety symptoms in individuals. Total scores range from 0 to 21, with higher scores indicating more severe anxiety symptoms.

Baseline to Week 8 visit 10
Response
기간: Baseline to Week 8 visit 10

The number of subjects who had a treatment response defined as a 50% reduction in Montgomery-Asberg Depression Rating Scale (MADRS) score (Range: 0-60).

Baseline to Week 8 visit 10
Improvement of Clinical Global Impression for Bipolar Disorder (CGI-I) Score
기간: Baseline to Week 8 visit 10

The number of subjects who had improvement in their CGI-I score. This scale evaluates how much the patient's illness has improved or worsened relative to their baseline state (prior to starting treatment). Scores range from 1-7 with lower scores indicating higher improvement.

Baseline to Week 8 visit 10
Change in Young Mania Rating Scale (YMRS) Score
기간: Baseline to Week 8

The Young Mania Rating Scale (YMRS) is an 11-item clinician-administered questionnaire used to assess and measure the severity of manic symptoms. Scores range from 0 to 60, with higher scores indicating greater symptom severity. The outcome measure was mean percent change from baseline in the total YMRS score. A greater decrease from baseline (more negative percent change) indicates improvement in manic symptoms.

Baseline to Week 8
Change in Young Mania Rating Scale (YMRS) Score-Open Label Extension
기간: Week 8 to Week 16

The Young Mania Rating Scale (YMRS) is an 11-item clinician-administered questionnaire used to assess and measure the severity of manic symptoms. Scores range from 0 to 60, with higher scores indicating greater symptom severity. The outcome measure was mean change from week 8 to week 16 in the total YMRS score.

Week 8 to Week 16
Change in Epworth Sleepiness Scale (ESS) Score
기간: Baseline to Week 8

The Epworth Sleepiness Scale (ESS) is a self-administered questionnaire that measures the average level of daytime sleepiness. By rating the likelihood of dozing off in 8 daily scenarios, a total score ranging from 0 to 24 is calculated. A higher score indicates greater daytime sleepiness and increased severity of sleepiness symptoms. The outcome measure was the mean percent change from baseline in the total ESS score. A greater decrease from baseline (more negative percent change) indicates improvement in daytime sleepiness.

Baseline to Week 8
Change in Fatigue Severity Scale (FSS) Score
기간: Baseline to Week 8

The Fatigue Severity Scale (FSS) evaluates how fatigue impacts daily life. It contains 9 statements, each rated on a 1-to-7 scale (1 = strongly disagree, 7 = strongly agree). Total scores range from 9 to 63 with higher scores indicating worse fatigue. The outcome measure was the mean percent change from baseline in the total FSS score. A greater decrease from baseline (more negative percent change) indicates improvement in fatigue severity.

Baseline to Week 8
Change in Binge Eating Scale (BES) Score
기간: Baseline to Week 8

The Binge Eating Scale (BES) is a self-reported questionnaire designed to assess the presence and severity of binge eating behaviors and characteristics associated with binge eating. Total scores range from 0 to 48 with higher scores indicating greater severity of binge eating symptoms.

Baseline to Week 8
Change in Rapid Eating and Activity Assessment for Patients (REAP) Score
기간: Baseline to Week 8

The Rapid Eating and Activity Assessment for Patients (REAP) is a self-reported questionnaire used to assess dietary habits and physical activity behaviors. Total REAP scores range from 0 to 27 with higher scores indicating healthier nutrition and physical activity behaviors. The outcome measure was the mean percent change from baseline in the total REAP score. A greater increase from baseline indicates improvement in dietary and physical activity behaviors.

Baseline to Week 8
Change in Digit Symbol Substitution Test (DSST) Score
기간: Baseline to Week 8

The Digit Symbol Substitution Test (DSST) is a neuropsychological assessment of cognitive performance that measures processing speed, working memory, and visuomotor coordination. Participants are required to match symbols to corresponding number according to a provided key within a fixed time period of 90 seconds. The raw score is simply the total number of correctly matched symbols completed within the time limit (90 seconds). Scores range from 0 to the total number of correct responses achieved, with higher scores indicating better cognitive performance. The outcome measure was the mean percent change from baseline in DSST score. A greater increase from baseline indicates improvement in cognitive performance.

Baseline to Week 8
Morningness-Eveningness Questionnaire (MEQ) Score
기간: Baseline

The Morningness-Eveningness Questionnaire (MEQ) is a self-assessment tool used to determine a person's preferred timing for sleep and peak alertness during the day. Total scores range from 16 to 86 with higher scores indicating a stronger morning preference, whereas lower scores indicate a stronger evening preference.

Baseline

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 수석 연구원: Mark A Frye, Mayo Clinic

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2020년 11월 17일

기본 완료 (실제)

2025년 7월 25일

연구 완료 (실제)

2025년 7월 25일

연구 등록 날짜

최초 제출

2019년 12월 4일

QC 기준을 충족하는 최초 제출

2020년 1월 16일

처음 게시됨 (실제)

2020년 1월 22일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 16일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 22일

마지막으로 확인됨

2026년 7월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

예

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다